The pharmaceutical companies Biogen and Eisai last week announced that a monoclonal antibody treatment reduced cognitive decline by 27% in people with early stage Alzheimer’s compared with those on a placebo after 18 months. www.science.org/content/article/news-glance-ai-regulation-renewable-energy-and-alzheimer-s-therapy? Lecanemab belongs to a class...
Article by Lalita Panicker, Consulting Editor, Views and Editor, Insight, Hindustan Times, New Delhi A technique for precisely rewriting the genetic code directly in the body has slashed “bad” cholesterol levels—possibly for life—in three people prone to dangerously high levels...

Must Read

Hello

0FansLike
0FollowersFollow
0FollowersFollow
0SubscribersSubscribe

Hot This Week

Past Stories